Cambridge, MA—(January 28, 2016) BioPact is the 2016 recipient of the Drug Delivery Partnerships Technology Innovation Award. The award celebrates game-changing technological innovation in drug delivery over the past year. For 20 years, Drug Delivery Partnerships (DDP) has been the world’s largest drug delivery meeting to accelerate drugs to market and lengthen lifecycles by finding new partners, new drug delivery technologies, and new formulation development strategies.
BioPact’s Chief Executive Officer, Joe Dillon, Ph.D., MBA, accepted the award on behalf of the company. Dr. Dillon said, “We at BioPact wish to thank Drug Delivery Partnerships for selecting our ground-breaking nano-drug delivery technology, MGMR®, for this award out of all of the other deserving nominees. Our unique and proprietary composition of discrete carbon nanotubes has many important medical applications in areas of high unmet patient need. And we look forward to working with our partners to develop innovative therapies.”
Lainie Mulvanny, BioPact’s Vice President of Business Development, was also in attendance at this year’s meeting. She said, “Bringing this disruptive technology to DDP has changed the drug delivery landscape. We look forward to future endeavors with new partners.”
BioPact is a nanotechnology development company based in Cambridge, MA. BioPact’s Medical Grade Molecular Rebar (MGMR®), is a unique composition of matter derived from carbon nanotubes. MGMR® are discrete (individual), length controlled, surface functionalized, open-ended, medical grade carbon nanotubes. The unique physical and chemical properties of these tubes overcome the limitations of traditional dirty, tangled carbon nanotube bundles. BioPact is focused on developing and partnering MGMR® for use in drug delivery, orthotics, regenerative medicine, devices, diagnostics, bio-sensors, material optimization and a number of other medical applications addressing substantial unmet needs in patient care. Please visit us at www.bio-pact.com